Kirstin A Zettlitz1, Christopher M Waldmann2, Wen-Ting K Tsai2, Richard Tavaré2, Jeffrey Collins2, Jennifer M Murphy2, Anna M Wu2. 1. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California kzettlitz@coh.org. 2. Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California.
Abstract
Antibody-based dual-modality (PET/fluorescence) imaging enables both presurgery antigen-specific immuno-PET for noninvasive whole-body evaluation and intraoperative fluorescence for visualization of superficial tissue layers for image-guided surgery. Methods: We developed a universal dual-modality linker (DML) that facilitates site-specific conjugation to a cysteine residue-bearing antibody fragment, introduction of a commercially available fluorescent dye (via an amine-reactive prosthetic group), and rapid and efficient radiolabeling via click chemistry with 18F-labeled trans-cyclooctene (18F-TCO). To generate a dual-modality antibody fragment-based imaging agent, the DML was labeled with the far-red dye sulfonate cyanine 5 (sCy5), site-specifically conjugated to the C-terminal cysteine of the anti-prostate stem cell antigen (PSCA) cys-diabody A2, and subsequently radiolabeled by click chemistry with 18F-TCO. The new imaging probe was evaluated in a human PSCA-positive prostate cancer xenograft model by sequential immuno-PET and optical imaging. Uptake in target tissues was confirmed by ex vivo biodistribution. Results: We successfully synthesized a DML for conjugation of a fluorescent dye and 18F. The anti-PSCA cys-diabody A2 was site-specifically conjugated with either DML or sCy5 and radiolabeled via click chemistry with 18F-TCO. Immuno-PET imaging confirmed in vivo antigen-specific targeting of prostate cancer xenografts as early as 1 h after injection. Rapid renal clearance of the 50-kDa antibody fragment enables same-day imaging. Optical imaging showed antigen-specific fluorescent signal in PSCA-positive xenografts and high contrast to surrounding tissue and PSCA-negative xenografts. Conclusion: The DML enables site-specific conjugation away from the antigen-binding site of antibody fragments, with a controlled linker-to-protein ratio, and combines signaling moieties for 2 imaging systems into 1 molecule. Dual-modality imaging could provide both noninvasive whole-body imaging with organ-level biodistribution and fluorescence image-guided identification of tumor margins during surgery.
Antibody-based dual-modality (PET/fluorescence) imaging enables both presurgery antigen-specific immuno-PET for noninvasive whole-body evaluation and intraoperative fluorescence for visualization of superficial tissue layers for image-guided surgery. Methods: We developed a universal dual-modality linker (DML) that facilitates site-specific conjugation to a cysteine residue-bearing antibody fragment, introduction of a commercially available fluorescent dye (via an amine-reactive prosthetic group), and rapid and efficient radiolabeling via click chemistry with 18F-labeled trans-cyclooctene (18F-TCO). To generate a dual-modality antibody fragment-based imaging agent, the DML was labeled with the far-red dye sulfonate cyanine 5 (sCy5), site-specifically conjugated to the C-terminal cysteine of the anti-prostate stem cell antigen (PSCA) cys-diabody A2, and subsequently radiolabeled by click chemistry with 18F-TCO. The new imaging probe was evaluated in a humanPSCA-positive prostate cancer xenograft model by sequential immuno-PET and optical imaging. Uptake in target tissues was confirmed by ex vivo biodistribution. Results: We successfully synthesized a DML for conjugation of a fluorescent dye and 18F. The anti-PSCAcys-diabody A2 was site-specifically conjugated with either DML or sCy5 and radiolabeled via click chemistry with 18F-TCO. Immuno-PET imaging confirmed in vivo antigen-specific targeting of prostate cancer xenografts as early as 1 h after injection. Rapid renal clearance of the 50-kDa antibody fragment enables same-day imaging. Optical imaging showed antigen-specific fluorescent signal in PSCA-positive xenografts and high contrast to surrounding tissue and PSCA-negative xenografts. Conclusion: The DML enables site-specific conjugation away from the antigen-binding site of antibody fragments, with a controlled linker-to-protein ratio, and combines signaling moieties for 2 imaging systems into 1 molecule. Dual-modality imaging could provide both noninvasive whole-body imaging with organ-level biodistribution and fluorescence image-guided identification of tumor margins during surgery.
Authors: L E Williams; A M Wu; P J Yazaki; A Liu; A A Raubitschek; J E Shively; J Y Wong Journal: Cancer Biother Radiopharm Date: 2001-02 Impact factor: 3.099
Authors: Tove Olafsen; Chia-Wei Cheung; Paul J Yazaki; Lin Li; Gobalakrishnan Sundaresan; Sanjiv S Gambhir; Mark A Sherman; Lawrence E Williams; John E Shively; Andrew A Raubitschek; Anna M Wu Journal: Protein Eng Des Sel Date: 2004-01 Impact factor: 1.650
Authors: Wenting K Tsai; Kirstin A Zettlitz; Richard Tavaré; Naoko Kobayashi; Robert E Reiter; Anna M Wu Journal: Theranostics Date: 2018-11-12 Impact factor: 11.556
Authors: Patrick J Madden; Muhammad S Arif; Mark E Becker; Michael D McRaven; Ann M Carias; Ramon Lorenzo-Redondo; Sixia Xiao; Cecily C Midkiff; Robert V Blair; Elizabeth Lake Potter; Laura Martin-Sancho; Alan Dodson; Elena Martinelli; John-Paul M Todd; Francois J Villinger; Sumit K Chanda; Pyone Pyone Aye; Chad J Roy; Mario Roederer; Mark G Lewis; Ronald S Veazey; Thomas J Hope Journal: Front Immunol Date: 2021-12-24 Impact factor: 7.561
Authors: Sai Kiran Sharma; Pierre Adumeau; Outi Keinänen; Vikram Sisodiya; Hetal Sarvaiya; Robert Tchelepi; Joshua A Korsen; Jacob Pourat; Kimberly J Edwards; Ashwin Ragupathi; Omar Hamdy; Laura R Saunders; Charles M Rudin; John T Poirier; Jason S Lewis; Brian M Zeglis Journal: Bioconjug Chem Date: 2021-04-09 Impact factor: 4.774